Patrick Oh, MD

Articles by Patrick Oh, MD

Further Research May Explore Systemic Therapy Failure Following RT in NSCLC

October 23rd 2024

Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.

Increased use of systemic therapies, particularly among patients with high-risk node-negative NSCLC, were observed following radiotherapy.

Data Show Increasing Systemic Therapy Use in NSCLC Radiotherapy Population

ByPatrick Oh, MD

October 22nd 2024

Increased use of systemic therapies, particularly among patients with high-risk node-negative NSCLC, were observed following radiotherapy.

Interest in novel therapies to improve outcomes initiated an investigation of the use of immunotherapy in early-stage non-small cell lung cancer.

Evaluating Immunotherapy as Systemic Therapy Plus RT in Early-Stage NSCLC

ByPatrick Oh, MD

October 21st 2024

Interest in novel therapies to improve outcomes initiated an investigation of the use of immunotherapy in early-stage non-small cell lung cancer.

Patrick Oh, MD

Articles by Patrick Oh, MD

Further Research May Explore Systemic Therapy Failure Following RT in NSCLC

Data Show Increasing Systemic Therapy Use in NSCLC Radiotherapy Population

Evaluating Immunotherapy as Systemic Therapy Plus RT in Early-Stage NSCLC

Latest Updated Articles

Trending on CancerNetwork

AI-Powered Scout Platform Could Enhance Oncology Decision-Making With Data- and Expert-Driven Insights

FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars

Novel SSTR-Targeted Alpha Therapy Shows “Encouraging” Activity in GEP-NETs

BL-B01D1 Shows Preliminary Efficacy, Favorable Safety in Urothelial Cancer

Durvalumab Plus Concurrent CRT Does Not Add Benefit in Stage III NSCLC